Nuclear export inhibition activates TP53 pathways and is a potent therapeutic strategy in atypical teratoid rhabdoid tumors.

House TO, Alimova I, Larsen S, Murdock G, Pierce A, Brunt B, Tocci S, Krykunenko S, Coppola M, Erdreich-Epstein A, Firestein R, Serkova NJ, Vibhakar R, Tsai JW

Open source

DOI: 10.1093/noajnl/vdag209
Published: 2026 Jan-Dec
Container: Neuro-oncology advances
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/noajnl/vdag209,
  title = {Nuclear export inhibition activates TP53 pathways and is a potent therapeutic strategy in atypical teratoid rhabdoid tumors.},
  author = {House TO and Alimova I and Larsen S and Murdock G and Pierce A and Brunt B and Tocci S and Krykunenko S and Coppola M and Erdreich-Epstein A and Firestein R and Serkova NJ and Vibhakar R and Tsai JW},
  year = {2026},
  journal = {Neuro-oncology advances},
  doi = {10.1093/noajnl/vdag209},
  url = {https://doi.org/10.1093/noajnl/vdag209}
}

RIS

TY  - JOUR
TI  - Nuclear export inhibition activates TP53 pathways and is a potent therapeutic strategy in atypical teratoid rhabdoid tumors.
AU  - House TO
AU  - Alimova I
AU  - Larsen S
AU  - Murdock G
AU  - Pierce A
AU  - Brunt B
AU  - Tocci S
AU  - Krykunenko S
AU  - Coppola M
AU  - Erdreich-Epstein A
AU  - Firestein R
AU  - Serkova NJ
AU  - Vibhakar R
AU  - Tsai JW
PY  - 2026
JO  - Neuro-oncology advances
DO  - 10.1093/noajnl/vdag209
UR  - https://doi.org/10.1093/noajnl/vdag209
ER  -

APA

TO, H., I, A., S, L., G, M., A, P., B, B., S, T., S, K., M, C., A, E., R, F., NJ, S., R, V., & JW, T. (2026). Nuclear export inhibition activates TP53 pathways and is a potent therapeutic strategy in atypical teratoid rhabdoid tumors.. Neuro-oncology advances. https://doi.org/10.1093/noajnl/vdag209

Source records

pubmed · retrieved 2026-09-25T08:43:56.563Z